Florida Cuts HIV Medication Program Eligibility
Analysis based on 7 articles · First reported Feb 26, 2026 · Last updated Mar 02, 2026
The United States===Florida Department of Health's emergency rule to cut United States===AIDS Drug Assistance Programs (ADAP) funding and eligibility is expected to negatively impact the healthcare sector, particularly pharmaceutical companies like Gilead Sciences that produce HIV medications like Bictegravir/emtricitabine/tenofovir alafenamide. The potential rise in HIV infections and healthcare costs in United States===Florida could also strain public health budgets and insurance providers.
The United States===Florida Department of Health has issued an emergency rule drastically cutting eligibility for the state's United States===AIDS Drug Assistance Programs (ADAP), a federal-state partnership providing free HIV medication to low-income individuals. Eligibility has been reduced from 400% to 130% of the federal poverty level, potentially affecting 16,000 of 30,000 Floridians enrolled. The rule also limits insurance coverage for Bictegravir/emtricitabine/tenofovir alafenamide, a key HIV treatment. State officials, including Joseph Ladapo, cite a $120 million federal funding shortfall and rising healthcare costs as reasons. However, HIV advocates, such as the AIDS Healthcare Foundation and Anna K. Person of the HIV Medicine Association, dispute this explanation and warn of a public health disaster, including increased HIV diagnoses and healthcare costs. The AIDS Healthcare Foundation has filed a lawsuit challenging the legality of these changes. The United States===Florida House of Representatives and United States===Florida Senate have earmarked funds to address the gap, but the immediate impact on patients remains a concern.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard